Citations

Clear

7552 citation(s) found for "Ku, Matthew".

The Delphi Delirium Management Algorithms. A practical tool for clinicians, the result of a modified Delphi expert consensus approach.
Ottens, Thomas H. , Hermes, Carsten , Page, Valérie , Oldham, Mark , Arora, Rakesh C. , Bienvenu, O. Joseph , Boogaard, Mark van den , Caplan, Gideon A. , Hansen, Hans-Christian , Inouye, Sharon K. , Kamholz, Barbara, Maas, Matthew B. , MacLullich, Alasdair M. J. , Negro, Alessandra , Neufeld, Karin J. , Nydahl, Peter , Radtke, Finn M. , Raedt, Sylvie De , Rosenthal, Lisa , Vardy, Emma , Slooter, Arjen J. C. , Arora, Rakesh , van den Boogaard, Mark , Caplan, Gideon , Friedrich, Michaela-Elena , Hanison, James , Hansen, Hans-Christian , Inouye, Sharon K , Kotfis, Katarzyna , MacLullich, Alasdair M J , Marcantonio, Edward R , van Munster, Barbara C , Müller-Werdan, Ursula , Nydahl, Peter , Oh, Esther S , Pandharipande, Pratik , Radtke, Finn M , Raedt, Sylvie De , Spies, Claudia D , Vardy, Emma R L C , Wijdicks, Eelco Fm , Slooter, Arjen J C , Devlin, John W. , Kotfis, Katarzyna , Marcantonio, Edward R. , Morandi, Alessandro , Rosenthal, Lisa J., Sanders, Robert D. , Spies, Claudia , Wijdicks, Eelco F. M.

Mayo Clinic

Delirium | January 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.56392/001c.90652 | PMID 38348284 Get It

Delirium is common in hospitalised patients, and there is currently no specific treatment. Identifying and treating underlying somatic causes of delirium is the first priority once delirium is diagnosed. Several international guidelines provide clinicians with an evidence-based approach to screening, diagnosis and symptomatic treatment. However, current guidelines do not offer a structured approach to identification of underlying causes. A panel of 37 internationally recognised delirium experts from diverse medical backgrounds worked together in a modified Delphi approach via an online platform. Consensus was reached after five voting rounds. The final product of this project is a set of three delirium management algorithms (the Delirium Delphi Algorithms), one for ward patients, one for patients after cardiac surgery and one for patients in the intensive care unit.
Pathophysiology of Facial Nerve Stimulation and Its Implications for Electrical Stimulation in Cochlear Implants
Saoji, Aniket A. , DeJong, Melissa D., Bertsch, Natasha J., Graham, Madison K., Goulson, Kayla R., Pease, Megan L. Wernsman, Gruenwald, Jill M., Bross, Abigail E., Dornhoffer, James R. , Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Lane, John I. , Pesch, Joerg, Vanpoucke, Filiep J.

Mayo Clinic

Otology & Neurotology | January 11, 2024 | Volume: 45 | Issue: 2 | Pages: e84-e90

10.1097/mao.0000000000004082 | PMID 38206062 Get It

Objectives A small number of cochlear implant (CI) users experience facial nerve stimulation (FNS), which can manifest as facial twitching. In some patients, this can be resolved by adjusting the electrical stimulation parameters. However, for others, facial stimulation can significantly impair CI outcomes or even prevent its use. The exact mechanisms underlying FNS are unclear and may vary among patients. Design Transimpedance measurements were used to assess lateral and longitudinal spread of current within 15 cochlea of nucleus CI recipients with FNS (13 unilateral recipients and 1 bilateral recipient). We compared the transimpedance measurements with programming parameters from clinical visits and pre- and postoperative temporal bone computed tomography (CT) scans to identify factors that may contribute to FNS in each CI ear. Results In nine ears, transimpedance curves showed inflection, which suggests a localized current sink within the cochlea. This indicates a low-impedance pathway through which current exits the cochlea and stimulates the labyrinthine segment of the facial nerve canal. Electrodes near this current sink were disabled or underfit to minimize facial stimulation. In the other seven ears, current flow peaked toward the basal end of the cochlea, suggesting that current exits through the round window or other structures near the basal end of the cochlea, stimulating the tympanic segment of the facial nerve. Conclusions Objective transimpedance measurements can be used to elucidate the mechanisms of FNS and to develop strategies for optimizing electrical stimulation parameters and speech coding to minimize or eliminate FNS in a small subset of CI users.
Systematic Review of Auditory Training Outcomes in Adult Cochlear Implant Recipients and Meta-Analysis of Outcomes
Dornhoffer, James R. , Chidarala, Shreya , Patel, Terral , Khandalavala, Karl R. , Nguyen, Shaun A. , Schvartz‐Leyzac, Kara C. , Dubno, Judy R. , Carlson, Matthew L. , Moberly, Aaron C. , Moberly, Aaron C , McRackan, Theodore R.

Mayo Clinic

Journal of Clinical Medicine | January 11, 2024 | Volume: 13 | Issue: 2 | Pages: 400

10.3390/jcm13020400 | PMID 38256533 Get It

Objective: to review evidence on the efficacy of auditory training in adult cochlear implant recipients. Data Sources: PRISMA guidelines for a systematic review of the literature were followed. PubMed, Scopus, and CINAHL databases were queried on 29 June 2023 for terms involving cochlear implantation and auditory training. Studies were limited to the English language and adult patient populations. Study Selection: Three authors independently reviewed publications for inclusion in the review based on a priori inclusion and exclusion criteria. Inclusion criteria encompassed adult cochlear implant populations, an analysis of clinician- or patient-directed auditory training, and an analysis of one or more measures of speech recognition and/or patient-reported outcome. Exclusion criteria included studies with only pediatric implant populations, music or localization training in isolation, and single-sample case studies. Data Extraction: The data were collected regarding study design, patient population, auditory training modality, auditory training timing, speech outcomes, and data on the durability of outcomes. A quality assessment of the literature was performed using a quality metric adapted from the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group guidelines. Data Synthesis and Meta-Analysis: Data were qualitatively summarized for 23 studies. All but four studies demonstrated significant improvement in at least one measured or patient-reported outcome measure with training. For 11 studies with sufficient data reporting, pre-intervention and post-intervention pooled means of different outcome measures were compared for 132 patients using meta-analysis. Patient-direct training was associated with significant improvement in vowel-phoneme recognition and speech recognition in noise (p < 0.05 and p < 0.001, respectively), and clinician-directed training showed significant improvement in sentence recognition in noise (p < 0.001). Conclusions: The literature on auditory training for adult cochlear implant recipients is limited and heterogeneous, including a small number of studies with limited levels of evidence and external validity. However, the current evidence suggests that auditory training can improve speech recognition in adult cochlear implant recipients.
Ultrasound Shear Elastography With Expanded Bandwidth (USEWEB): A Novel Method for 2D Shear Phase Velocity Imaging of Soft Tissues
Kijanka, Piotr , Urban, Matthew W. , Urban, Matthew W

Mayo Clinic

IEEE Transactions on Medical Imaging | January 10, 2024 | Volume: 43 | Issue: 5 | Pages: 1910-1922

10.1109/tmi.2024.3352097 | PMID 38198276 Get It

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Out
Rastogi, Priya , O’Shaughnessy, Joyce , Martín, Miguel , Boyle, Frances , Cortés, Javier , Goetz, Matthew P. , Hamilton, Erika , Tryakin, A. , Neven, Patrick , Huober, Jens , Shao, Zhimin, Muñoz, María del Mar , Antonio, Belén San , Shahir, Ashwin, Rugo, Hope S , Goetz, Matthew P , Hamilton, Erika P , Huang, Chiun-Sheng , Tryakin, Alexey , Cicin, Irfan , Testa, Laura , Neven, Patrick , Huober, Jens , Shao, Zhimin , Harbeck, Nadia , Johnston, Stephen , Martin, Miguel , Rugo, Hope S. , Huang, Chiun‐Sheng , Senkus, Elżbieta , Çiçin, İrfan , Wei, Ran , André, Valérie, Johnston, Stephen , Cortés, J.

Mayo Clinic

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 9 | Pages: 987-993

10.1200/jco.23.01994 | PMID 38194616 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) that persisted beyond the 2-year treatment period in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, node-positive, high-risk early breast cancer (EBC). Here, we report 5-year efficacy results from a prespecified overall survival (OS) interim analysis. In the intent-to-treat population, with a median follow-up of 54 months, the benefit of abemaciclib was sustained with hazard ratios of 0.680 (95% CI, 0.599 to 0.772) for IDFS and 0.675 (95% CI, 0.588 to 0.774) for DRFS. This persistence of abemaciclib benefit translated to continuous separation of the curves with a deepening in 5-year absolute improvement in IDFS and DRFS rates of 7.6% and 6.7%, respectively, compared with rates of 6% and 5.3% at 4 years and 4.8% and 4.1% at 3 years. With fewer deaths in the abemaciclib plus ET arm compared with the ET-alone arm (208 v 234), statistical significance was not reached for OS. No new safety signals were observed. In conclusion, abemaciclib plus ET continued to reduce the risk of developing invasive and distant disease recurrence beyond the completion of treatment. The increasing absolute improvement at 5 years is consistent with a carryover effect and further supports the use of abemaciclib in patients with high-risk EBC.
Marlex Mesh Reconstruction of the Extensor Mechanism
Abdel, Matthew P. , Carender, Christopher N. , Bedard, Nicholas A. , Perry, Kevin I. , Pagnano, Mark W., Hanssen, Arlen D. , Abdel, Matthew P , Bedard, Nicholas A , Pagnano, Mark W.

Mayo Clinic

Journal of Bone and Joint Surgery | January 9, 2024 | Volume: 106 | Issue: 7 | Pages: 608-616

10.2106/jbjs.23.01006 | PMID 38194506 Get It

Marlex mesh reconstruction of the extensor mechanism following total knee arthroplasty (TKA) has demonstrated excellent early results. The purpose of the present study was to evaluate longer-term results of Marlex mesh reconstruction of the extensor mechanism in 93 TKAs. Seventy-seven reconstructions were aseptic, and 16 were performed as part of a 2-stage exchange for the treatment of infection. Mean follow-up was 8 years. Twenty-eighty patients experienced mesh failure. Seventeen failures were treated with mesh revision (8 for patellar tendon rupture, 7 for quadriceps tendon rupture, and 2 for symptomatic lengthening). The 10-year cumulative incidence of mesh revision for mesh failure was 20%. Extensor lag improved by a mean of 28°, with a mean extensor lag of 9° at most recent follow-up. At a mean follow-up of 8 years, Marlex mesh reconstruction was a durable and reliable technique to treat both aseptic and septic ruptures of the extensor mechanism. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Navigating Now and Next: Recent Advances and Future Horizons in Robotic Radical Prostatectomy
Mian, Abrar , Tollefson, Matthew K. , Shah, Paras , Sharma, Vidit , Mian, Ahmed, Mian, Ahmed, Thompson, R. Houston, Boorjian, Stephen A. , Frank, Igor, Khanna, Abhinav, Mian, Abrar H , Mian, Ahmed, Mian, Ahmed

Mayo Clinic

Journal of Clinical Medicine | January 9, 2024 | Volume: 13 | Issue: 2 | Pages: 359

10.3390/jcm13020359 | PMID 38256493 Get It

Robotic-assisted radical prostatectomy (RARP) has become the leading approach for radical prostatectomy driven by innovations aimed at improving functional and oncological outcomes. The initial advancement in this field was transperitoneal multiport robotics, which has since undergone numerous technical modifications. These enhancements include the development of extraperitoneal, transperineal, and transvesical approaches to radical prostatectomy, greatly facilitated by the advent of the Single Port (SP) robot. This review offers a comprehensive analysis of these evolving techniques and their impact on RARP. Additionally, we explore the transformative role of artificial intelligence (AI) in digitizing robotic prostatectomy. AI advancements, particularly in automated surgical video analysis using computer vision technology, are unprecedented in their scope. These developments hold the potential to revolutionize surgeon feedback and assessment and transform surgical documentation, and they could lay the groundwork for real-time AI decision support during surgical procedures in the future. Furthermore, we discuss future robotic platforms and their potential to further enhance the field of RARP. Overall, the field of minimally invasive radical prostatectomy for prostate cancer has been an incubator of innovation over the last two decades. This review focuses on some recent developments in robotic prostatectomy, provides an overview of the next frontier in AI innovation during prostate cancer surgery, and highlights novel robotic platforms that may play an increasing role in prostate cancer surgery in the future.
Development and validation of a scale to assess the belief that ‘age causes illness’
Stewart, Tara L., Schumann, Matthew E. , Ruthig, Joelle C.

Mayo Clinic

Psychology & Health | January 8, 2024 | Volume: 40 | Issue: 7 | Pages: 1143-1155

10.1080/08870446.2023.2300037 | PMID 38189349 Get It

Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials
Atallah‐Yunes, Suheil Albert , Khurana, Arushi , Maurer, Matthew J. , Maurer, Matthew , Atallah-Yunes, Albert

Mayo Clinic

Leukemia & Lymphoma | January 5, 2024 | Volume: 65 | Issue: 4 | Pages: 430-439

10.1080/10428194.2023.2298705 | PMID 38180317 Get It